Analysis Pregabalin: what the patent litigation means for doctors and drug companies BMJ 2018; 361 doi: https://doi.org/10.1136/bmj.k2318 (Published 07 June 2018) Cite this as: BMJ 2018;361:k2318 Article Related content Metrics Responses Peer review Related articles Views & Reviews Margaret McCartney: Second use patents—why do we have to prescribe branded Lyrica for pain? Published: 20 May 2015; BMJ 350 doi:10.1136/bmj.h2734 See more When I use a word . . . . Counterfactual medical history: Milton’s poetry BMJ June 24, 2022, 377 o1569; DOI: https://doi.org/10.1136/bmj.o1569 Benjamin Jon Tinsley BMJ June 24, 2022, 377 o1541; DOI: https://doi.org/10.1136/bmj.o1541 Ernest Theodore Roberts BMJ June 24, 2022, 377 o1540; DOI: https://doi.org/10.1136/bmj.o1540 James Irvine Currie BMJ June 24, 2022, 377 o1522; DOI: https://doi.org/10.1136/bmj.o1522 Ian Norman McCulloch BMJ June 24, 2022, 377 o1539; DOI: https://doi.org/10.1136/bmj.o1539 Cited by... Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysisAbstract Fulltext PDF
